Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reviva Pharmaceuticals Holdings, Inc. filings document a Nasdaq-listed biopharmaceutical issuer developing drug candidates for CNS, inflammatory and cardiometabolic diseases. Its 8-K reports furnish operating and financial results, Regulation FD updates, and material-event disclosures tied to the brilaroxazine schizophrenia program, intellectual-property strategy, public offerings, and capital structure.
Proxy and other filings cover shareholder voting matters, director elections, auditor ratification, executive compensation, authorized share amendments, certificate amendments, security-holder rights, and Nasdaq listing-compliance notices. The filings also identify the company's common stock under symbol RVPH and describe common-stock, warrant and governance disclosures relevant to its public-company reporting.
Reviva Pharmaceuticals Holdings, Inc. Schedule 13G reports that CVI Investments, Inc. and Heights Capital Management, Inc. together beneficially hold 666,667 shares of common stock, representing 5.2% of the class. The filing states there were 12,727,044 Shares outstanding as of the completion of the offering per the Prospectus Supplement dated March 19, 2026. Heights Capital Management, Inc. is disclosed as investment manager to CVI Investments, Inc. and "may exercise voting and dispositive power" over the shares; the Reporting Persons disclaim beneficial ownership except for their pecuniary interest. The filing is signed by Sarah Travis on March 25, 2026.
Reviva Pharmaceuticals Holdings, Inc. investor Parag Saxena filed an amended Schedule 13D reporting beneficial ownership of 363,280 shares of common stock, or about 2.8% of the 12,810,377 shares outstanding as of March 20, 2026. His holdings include directly owned shares, interests held through various Vedanta-related entities, shares underlying warrants and pre-funded warrants, and fully vested options exercisable within 60 days of the filing date. The filing states that Saxena ceased to be a beneficial owner of more than five percent of Reviva’s common stock on March 20, 2026, and that he has not effected any transactions in the issuer’s securities during the 60 days preceding this amendment.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Chief Financial Officer Prabhu Narayan received a grant of stock options covering 40,925 shares of common stock on the grant date of March 18, 2026. These options have an exercise price of $1.87 per share and expire on March 17, 2036.
The award vests over time under the company’s 2020 Equity Incentive Plan. Of the total, 12,789 option shares vested immediately on the grant date, while the remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028, encouraging long-term alignment with the company.
REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.
One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.
Reviva Pharmaceuticals Holdings, Inc. has entered into agreements for a registered public offering raising aggregate gross proceeds of $10.0 million. The company will sell 6,283,334 shares of common stock and pre-funded warrants for up to 383,333 shares, together with Series G and Series H warrants exercisable for up to 6,666,667 shares each at an exercise price of $1.50 per share. Net proceeds are expected to be approximately $9.0 million, which Reviva plans to use, along with existing cash, to fund research and development, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and general corporate purposes. The warrants are immediately exercisable, with Series G expiring in five years and Series H in one year, and include beneficial ownership limits of 4.99% or 9.99%.
Reviva Pharmaceuticals Holdings, Inc. is offering 6,283,334 shares of common stock together with Series G and Series H common warrants and up to 383,333 Pre-Funded Warrants in a primary, best-efforts offering described in this prospectus supplement.
The combined public offering price is $1.50 per share and accompanying Series G and H Common Warrants; Series G warrants expire five years and Series H warrants expire 12 months after issuance. Pre-Funded Warrants carry a $0.0001 exercise price and may be used to avoid exceeding 4.99% (or, at purchaser election, 9.99%) beneficial ownership limits. The offering may terminate on April 13, 2026 and is expected to settle in a single closing; proceeds to the issuer are described as net of Placement Agent fees.
The prospectus supplement gives effect to a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding used to calculate post-offering figures are 6,443,710 as of March 17, 2026.
Reviva Pharmaceuticals Holdings, Inc. is offering shares of common stock together with Series G and Series H common warrants and pre-funded warrants in a public offering described in this preliminary prospectus supplement, subject to completion.
The offering is structured as bundled common stock (or pre-funded warrants) sold together with one Series G Common Warrant and one Series H Common Warrant per unit, with Series G exercisable for five years and Series H exercisable for 12 months. The company effected a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding were 6,443,710 as of March 16, 2026 (post-split). The offering is a best-efforts, no-minimum offering to be conducted at a fixed public offering price and expected to settle in a single closing. Use of proceeds is stated as funding R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and for working capital and general corporate purposes.
Reviva Pharmaceuticals Holdings, Inc. is offering shares of common stock together with Series G and Series H common warrants and pre-funded warrants in a public offering described in this preliminary prospectus supplement, subject to completion.
The offering is structured as bundled common stock (or pre-funded warrants) sold together with one Series G Common Warrant and one Series H Common Warrant per unit, with Series G exercisable for five years and Series H exercisable for 12 months. The company effected a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding were 6,443,710 as of March 16, 2026 (post-split). The offering is a best-efforts, no-minimum offering to be conducted at a fixed public offering price and expected to settle in a single closing. Use of proceeds is stated as funding R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and for working capital and general corporate purposes.
Reviva Pharmaceuticals Holdings approved a one-for-twenty reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 9, 2026. Every 20 existing shares will convert into 1 share, with no fractional shares issued; holdings will be rounded up to the next whole share.
The par value and authorized share count will not change, but outstanding options and warrants will be adjusted for the new ratio. Reviva is using the reverse split as a key step to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a delisting notice and a compliance extension through March 27, 2026.
The company warns that the reverse split announcement and implementation could pressure the stock price, reduce trading liquidity due to fewer outstanding shares, and that failure to meet Nasdaq’s listing standards could lead to delisting, harming liquidity, market value, and capital-raising ability.
683 Capital Management, 683 Capital Partners and Ari Zweiman filed Amendment No. 1 to a Schedule 13G updating their ownership in Reviva Pharmaceuticals Holdings, Inc. They may be deemed to beneficially own warrants to purchase 3,492,500 shares of common stock, all currently exercisable.
Based on 115,058,619 shares of common stock outstanding as of November 11, 2025, plus these warrant shares, their holdings represent about 3.0% of Reviva’s common stock. The filers state this amendment is an exit filing because they no longer own more than five percent and certify the securities are not held to change or influence control of the company.
Reviva Pharmaceuticals Holdings, Inc. reports that a Nasdaq Hearings Panel has granted the company an exception to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing through March 27, 2026. This gives the company more time to bring its share price back above the required level.
The company adds a new risk factor explaining that it may implement a reverse stock split to help meet the bid price rule and that such a split could negatively affect its share price and trading liquidity. Reviva warns that failure to regain or maintain compliance with Nasdaq listing standards could lead to delisting, which could hurt the stock’s liquidity, price, and the company’s ability to raise capital or pursue business opportunities.